Novel compounds useful as cc chemokine receptor ligands

A compound having the chemical formula:

• wherein
• R8 is aryl-X4—, heteroaryl-X4—, aryl, heterocycle or heteroaryl;
• X4 is —O—, —S—, —S(O)—, —S(O)2—, —S(O)2NRo— or —NRp, where Ro and Rp are each, independently, hydrogen or alkyl;
• Y4 is —C(O)—, —(CH2)2—, —(CH2)3—, —CH2C(O)—, —(CH2)2C(O)—, —C(O)CH2—, —C(O)—(CH2)2— or —CH2CH(OH)CH2—;
• R7 is hydrogen or alkyl;
• B is —C— or —O—;
• R9 is hydrogen, hydroxyl or cyano;
• X5 is —O—, —NRe—, —S—, —S(O)— or —S(O)2 where Re is hydrogen or alkyl;
• Z7 is aryl, heteroaryl, arylalkyl, heteroarylalkyl;
• p is 0 or 1;
• q is 0 or 1;
• Z4, Z5 and Z6 are each, independently, hydrogen, alkyl, arylalkyl, heteroarylalkyl, -(alkylene)-J-aryl or -(alkylene)-J-heteroaryl, where J is —O— or —NRq— and Rq is hydrogen or alkyl;
• provided, however, that when R9 is hydroxyl or cyano, then q is 0, B is —C—, and Z4, Z6 are both alkyl or both hydrogen;
• provided, however, that when R9 is H, then q is 1, p is 0, and B is —C—;
• provided, however, that when B is —O—, and both R9 and —X5—Z7 are absent;
• then Z5 is not hydrogen when p is 0;
• provided, however, that when B is —O—, R9 and —X5—Z7 are absent and p is 1;
• then either Z4, Z6 or Z5 are both not hydrogen;
• provided, however, that when B is —C—, Z4, Z6 are both hydrogen, and p is 0, then R9 is cyano, q is 0, Z7 is arylalkyl, and Y4 is —(CH2)3—;
• wherein, when present, any aryl, heterocycle or heteroaryl group may optionally be substituted by halogen, hydroxy, cyano, nitro, amino, alkylamino, dialkylamino, arylamino, diarylamino, amido, alkylamido, dialkylamido, carboxyl, alkyl, halogenated alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle, heterocyclealkyl, aroyl, acyl, alkoxy, aryloxy, heteroaryloxy, cycloalkyloxy, cycloalkylalkyloxy, arylalkyloxy, heteroarylalkyloxy, alkythio, arylthio, alkylsulfinyl, alkylsulfonyl, arylsulfinyl, arylsulfonyl, heteroarylsulfinyl, heteroarylsulfonyl, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, —NRrC(O)Rs, —NRtSO2Ru, where Rpr and Rt are each, independently, hydrogen or alkyl, Rs is amino, aminoalkyl, alkyl or cycloalkyl, and Ru is hydrogen or alkyl;
• and combinations thereof;
• and pharmaceutically acceptable salts or solvates or N-oxides thereof, or solvates of pharmaceutically acceptable salts thereof, or solvates of N-oxides thereof, or isomers, or prodrugs thereof;
• with the proviso that said compound is not
• 1-[2-(4-fluorophenoxy)ethyl]-N-(4-fluorophenyl)-4-piperidinamine,
• N-(4-chlorophenyl)-1-[2-(4-fluorophenoxy)ethyl]-4-piperidinamine,
• N-(4-chlorophenyl)-1-[3-(4-fluorophenoxy)propyl]-4-piperidinamine,
• N-(4-chlorophenyl)-1-(3-phenoxypropyl-4-piperidinamine,
• N-(4-fluoro-2-methylphenyl)-1-[3-(4-fluorophenoxy)propyl]-4-piperidinamine,
• 1-[3-(4-fluorophenoxy)propyl]-N-(4-fluorophenyl)-N-methyl-4-piperidinamine,
• 1-[3-(4-fluorophenoxy)propyl]-N-(4-fluorophenyl)-4-piperidinamine,
• N-(5-Chloro-2-{3-[4-(4-chloro-phenoxy)-piperidin-1-yl]-propoxy}-4-methoxy-phenyl)-acetamide,
• N-(5-Chloro-2-{3-[4-(4-chloro-phenylsulfanyl)-piperidin-1-yl]-propoxy}-4-methoxy-phenyl)-acetamide,
• N-(5-Chloro-2-{3-[4-(4-chloro-benzenesulfonyl)-piperidin-1-yl]-propoxy}-4-methoxy-phenyl)-acetamide,
• N-(5-Chloro-2-{3-[4-(4-chloro-phenoxy)-3,3-dimethyl-piperidin-1-yl]-propoxy}-4-methoxy-phenyl)-acetamide,
• N-(5-Chloro-2-{3-[4-(4-chloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-4-methoxy-phenyl)-acetamide,
• N-(5-Chloro-2-{3-[4-(4-cyano-phenoxy)-piperidin-1-yl]-propoxy}-4-methoxy-phenyl)-acetamide,
• N-(5-Chloro-2-{3-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-propoxy}-4-methoxy-phenyl)-acetamide,
• or a pharmaceutically acceptable salt thereof.